M&A / Deals Roche looks to Astex in $515m breast cancer deal PharmaphorumRoche's Genentech unit has forged an alliance with Astex, worth up to $515m, to partner on a fragment-based drug discovery programme in breast cancer.OncologyRead full story pharminent July 6, 2026 (Last updated: July 7, 2026) Pharmaphorum Roche’s Genentech unit has forged an alliance with Astex, worth up to $515m, to partner on a fragment-based drug discovery programme in breast cancer. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: UK, pharma industry pilot rapid access routes for medicinesNext: Novartis to acquire Myricx Bio in up to $1.5bn deal Related Stories M&A / Deals Novartis to acquire Myricx Bio in up to $1.5bn deal pharminent July 6, 2026 M&A / Deals AZ forges ever-closer ties with China’s CSPC Pharma pharminent July 2, 2026 M&A / Deals Insilico Medicine, Takeda partner on AI-driven drug discovery pharminent July 2, 2026
